SAFC and Novozymes Biopharma today announced a 10-year extension of their joint agreement under which SAFC retains exclusive marketing and distribution rights for Novozymes Biopharma’s LONG®R³IGF-I (LONG®R3) growth factor used for industrial cell culture applications.
The highly potent growth factor is manufactured specifically for customers in the cell culture market, to enable them to reduce operational and regulatory complexity and minimize manufacturing risk.
Read the full details of the agreement extension here.
